Trials / Terminated
TerminatedNCT01727154
Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 139 (actual)
- Sponsor
- Dendreon · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the immune response induced by sipuleucel-T (Provenge®).
Detailed description
Subjects will receive sipuleucel-T, and potentially other medications, as part of the clinical trial in which they are concurrently enrolled. For this study, cellular and humoral immune responses will be assessed. No additional study treatments will be conducted beyond what is required for the subject's concurrent clinical trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Sipuleucel-T | Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals. |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2017-07-01
- Completion
- 2017-07-01
- First posted
- 2012-11-15
- Last updated
- 2019-08-19
- Results posted
- 2019-08-19
Locations
39 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01727154. Inclusion in this directory is not an endorsement.